The European Union's health regulator on Friday backed authorization of Pfizer's (PFE.N) vaccine for respiratory syncytial virus (RSV) for use in babies and older adults. If the European Commission authorizes its use, the shot, called Abrysvo, could become the bloc's first to protect infants up to six months of age from the virus when given to pregnant women. The commission last month approved the region's first RSV vaccine, branded Arexvy, from rival GSK (GSK.L) for older people.